Dr. Reddy’s commenced its generics business in India in 1986 and is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high quality, affordable and innovative medicines across therapy areas.
As a fully integrated pharmaceutical company, Dr Reddy’s provides medicines through three core businesses:
Pharmaceutical Services and Active Ingredients, comprising our Active Pharmaceuticals and Custom Pharmaceuticals businesses;
– Global Generics, which includes branded and unbranded generics; and
– Proprietary Products, which includes New Chemical Entities (NCEs), Differentiated Formulations,
-Biopharmaceuticals
Peter DeYoung shares the significance of Indian giant Piramal Pharma’s recent demerger from its parent company and its current strategic focus on organic growth, brownfield expansions, and “complex hospital generics.”…
As secretary general of the Indian Pharmaceutical Alliance (IPA) Sudarshan Jain represents the interests of 25 leading Indian pharmaceutical companies, both at home and abroad. He outlines the association’s focus…
The IDMA’s Daara Patel outlines the association’s role in representing the diverse voices of the Indian pharmaceutical sector, advocating for manufacturers of all sizes. He explores the challenges and initiatives…
Indian pharma companies have been building a broader presence in LatAm markets over the past two decades. With well-established trade relations already in place, the region offers a series of unique…
A roundup of some of the top stories from the Indian pharma industry including the suspension of the National Medical Commission’s (NMC) guidelines making the prescription of generic drugs mandatory;…
Top stories from Indian pharma including Sanofi India’s plans to demerge its healthcare businesses; Junshi Biosciences and Dr. Reddy’s anti-PD-1 monoclonal antibody partnership; Venus Remedies’ new oncology approvals; CORONA and…
The latest news from the Indian pharma industry, including Dr. Reddy’s purchase of Mayne Pharma’s US portfolio; Sun Pharma’s acquisition of Concert Pharma; Bristol Myers Squibb’s expanded Indian footprint and…
The latest news from the Indian pharma industry, including WHO’s recommendation not to use cough syrup from Marion Biotech after further deaths, Indegene’s expanded presence in Europe, Sun Pharma’s FDA…
The latest news from the Indian pharma sector, including the potential for greater numbers of exports and better market access to the UK under a proposed free trade agreement, yet…
As one of the world’s a leading pharma manufacturers, India supplies about 20 percent of the global pharmaceuticals demand in terms of volume, yet the industry remains plagued with quality…
Top stories from Indian pharma including Dr Reddy’s move to US online platforms, Aspen/Serum Institute’s vaccine deal for Africa, Aurobindo’s USD 37.7 million investment in subsidiary CuraTeQ and Biocon’s FDA…
Arshia Bhandari of patient safety thought leadership forum PhVFIT examines how India is embracing a more patient-centric healthcare model via the implementation of a national patient safety implementation framework. …
See our Cookie Privacy Policy Here